Invesco India Pharma and Healthcare Fund
This is the Direct plan of Invesco India Pharma and Healthcare Fund — bought from the fund house, with no distributor commission in its expense ratio. Income is distributed, which is why this NAV sits below the growth plan of the same fund.
Performance
Key Metrics
Scheme Info
DefinitionsPeriod returns (<1Y, absolute — not annualized)
DefinitionsAnnualized returns (≥1Y — CAGR)
DefinitionsAdvanced metrics — risk and benchmark ratios
Fund vs category average (Sectoral/ Thematic)
| Period | Fund | Category avg. | Diff |
|---|---|---|---|
| 1M abs | +18.33% | — | — |
| 3M abs | — | — | — |
| 6M abs | — | — | — |
| 1Y CAGR | — | — | — |
| 3Y CAGR | — | — | — |
| 5Y CAGR | — | — | — |
Category average across peers in Sectoral/ Thematic, same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).
Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.
Backtest this fund
What a SIP or one-time investment would have grown to over this fund’s real NAV history.
2 monthly installments of ₹10,000 into Invesco India Pharma and Healthcare Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.
Taxation
Taxed as equityThis is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.
Flat, on the whole gain
On gains above ₹1.25 L per financial year
Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.
Asset allocation
As on 31 Oct 2026 · AMC disclosure- Equity97.04%
- Cash & Equivalents2.96%
AMC Profile
Invesco Mutual Fund is the Indian arm of Invesco, the US asset manager. It began life as Lotus India Mutual Fund, was bought by Religare in 2008 and ran as Religare Invesco until Invesco took full ownership in 2016.
Fund Managers
AKAditya KhemaniManaging since 07 Sep 2026
EVP & Fund Manager - Equity
More than 20 years
B.Com., PGDM - Finance (IIM, Lucknow)
November 1, 2023 onwards Invesco Asset Management (India) Pvt. Ltd. July 24, 2019 to October 31, 2023 EVP & Fund Manager - Equity - Motilal Oswal Asset Management India Company Limited October 1, 2007 to July 23, 2019 SVP and Fund Manager - Equity - HSBC Asset Management (India) Pvt. Ltd.
Fund managers from the AMC's filed Scheme Summary — its most recent filing for this scheme. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.
Explore from here
Invesco in the news
Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.
Motilal Oswal vs Invesco India Mid Cap Fund: Rs 10,000 monthly SIP would have grown to Rs 19 lakh in 7 years in one fund; check CAGR, top holdings, expense ratio and more
ET Now · 6h ago
Suspension of fresh and existing SIP/STP registrations in overseas funds of Invesco Mutual Fund
Value Research · 13d ago
Invesco Mutual Fund halts fresh SIPs, STPs in 3 overseas fund of funds (FoFs): What happens to existing investors?
Upstox · 15d ago
Invesco Mutual Fund suspends fresh subscriptions in international schemes
Value Research · 05 Oct 2026
Invesco Mutual Fund has resumed subscriptions in its international scheme
Value Research · 21 Sep 2026
Invesco India Large Cap Fund Direct Growth
Groww · 02 Sep 2026
Invesco India Multi Cap Fund Direct Growth
Groww · 02 Sep 2026
Invesco India Small Cap Fund Direct Growth
Groww · 02 Sep 2026
Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.
About Sectoral & Thematic funds
Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.
Frequently asked questions
What is the NAV of Invesco India Pharma and Healthcare Fund?
As of 19 Nov 2026, the NAV of Invesco India Pharma and Healthcare Fund is ₹10.65 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.
What returns has Invesco India Pharma and Healthcare Fund delivered?
Invesco India Pharma and Healthcare Fund has returned +6.29% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.
What is the expense ratio of Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund charges an expense ratio of 3.30% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.
What are the top holdings of Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund's largest holdings are Apollo Hospitals Enterprise Limited (9.1%), Divi's Laboratories Limited (8.7%), Max Healthcare Institute Limited (8.6%), Sai Life Sciences Limited (8.5%) and Sun Pharmaceutical Industries Limited (8.3%). Holdings are disclosed monthly and change over time.
How risky is Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund sits at the very high level on our estimate of SEBI's risk-o-meter scale, its trailing-3Y volatility (annualised) is 18.9% and its worst peak-to-trough fall in our sample was 11.4%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.
What is the benchmark of Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund is benchmarked against the BSE Healthcare TRI. The alpha, beta and capture figures on this page are measured against the Nifty Healthcare TRI, the closest index whose daily history we hold.
Who manages Invesco India Pharma and Healthcare Fund?
Invesco India Pharma and Healthcare Fund is managed by Aditya Khemani at Invesco.
When was Invesco India Pharma and Healthcare Fund launched, and what is its objective?
Invesco India Pharma and Healthcare Fund was launched on 07 Sep 2026. its stated objective is: To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved. Both are as filed in the scheme's own Scheme Summary Document.
How is Invesco India Pharma and Healthcare Fund taxed?
Invesco India Pharma and Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.